NASDAQ$IRTC
IRhythm Holdings Inc · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
iRhythm Technologies reported a 24% increase in Q4 2024 revenue with significant improvements in profitability metrics.
iRhythm Technologies reported Q4 2024 revenue of $164.3 million, a 24% increase year-over-year. The company improved its gross margin to 70.0%, and net loss narrowed significantly to $1.3 million from $38.7 million in Q4 2023. Adjusted EBITDA rose to $19.3 million, reflecting strong demand for Zio services. Cash and cash equivalents increased to $535.6 million, supporting continued investments in growth and technology.
- Q4 2024 revenue increased 24% YoY to $164.3 million.
- Gross margin improved to 70.0%, up from 66.0% in Q4 2023.
- Net loss narrowed to $1.3 million, a $37.4 million improvement YoY.
- Adjusted EBITDA reached $19.3 million, reflecting improved efficiency and demand.
Headline financials
Revenue & EPS history
iRhythm · Revenue · Quarterly
$164M
Forward guidance
iRhythm projects full-year 2025 revenue between $675 million and $685 million, with an adjusted EBITDA margin of 7% to 8%. The company aims to expand market presence and improve operational efficiencies.
Tailwinds
- Strong revenue growth expected to continue in 2025.
- Expansion into new international markets planned.
- Operational efficiencies expected to improve gross margins further.
- New product innovations and strategic licensing agreements support long-term growth.
- Increased demand for Zio Services across multiple customer segments.
Headwinds
- Potential pricing pressures in the competitive healthcare technology market.
- Higher research and development expenses may impact near-term profitability.
- Macroeconomic uncertainty could affect customer spending in healthcare.
- Operational challenges in scaling global expansion.
- Continued regulatory risks associated with medical device approvals and compliance.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
+1.6%
Avg return
Earnings day
-0.4%
Avg return
5 days after
-0.7%
Avg return
30 days after
50%
19 / 38 earnings
Positive
+20.4%
Q1 2025
Best reaction
-14.3%
Q2 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -6.9% | -8.9% | -11.8% | |
| Q4 2025 | -4.6% | -14.5% | -26.8% | |
| Q3 2025 | +0.6% | -2.0% | +2.1% | |
| Q1 2025 | +20.4% | +25.4% | +29.4% | |
| Q4 2024 | +6.0% | -2.9% | -7.3% | |
| Q3 2024 | -1.8% | -13.9% | +4.0% | |
| Q2 2024 | -14.3% | -15.6% | -17.8% | |
| Q1 2024 | -0.4% | -3.7% | -5.5% | |
| Q4 2023 | -5.3% | -1.7% | +10.2% | |
| Q3 2023 | -2.3% | -11.1% | -18.5% | |
| Q2 2023 | +13.9% | +10.7% | +1.2% | |
| Q1 2023 | -6.2% | -6.4% | -20.6% | |
| Q4 2022 | +8.2% | +9.2% | +12.5% | |
| Q3 2022 | -5.0% | -19.3% | -15.0% | |
| Q2 2022 | -3.3% | -8.4% | -1.1% | |
| Q1 2022 | -3.7% | +2.5% | +10.6% | |
| Q4 2021 | +13.2% | +16.1% | +29.1% | |
| Q3 2021 | -14.1% | -15.6% | -19.7% | |
| Q2 2021 | +0.7% | -3.6% | -4.7% | |
| Q1 2021 | +6.9% | +2.8% | -17.0% | |
| Q4 2020 | +5.2% | -2.7% | -10.9% | |
| Q3 2020 | +13.1% | +11.1% | -20.0% | |
| Q2 2020 | +6.3% | -4.4% | +11.8% | |
| Q1 2020 | +13.3% | +14.8% | +9.3% | |
| Q4 2019 | +9.7% | +10.1% | -13.8% | |
| Q3 2019 | +11.5% | +8.3% | +41.1% | |
| Q2 2019 | +3.4% | +7.8% | +1.2% | |
| Q1 2019 | -5.0% | -1.6% | +1.6% | |
| Q4 2018 | -2.2% | -9.4% | -25.7% | |
| Q3 2018 | +1.0% | +7.6% | -3.0% | |
| Q2 2018 | -1.8% | -3.8% | +9.5% | |
| Q1 2018 | -0.9% | -1.3% | +15.7% | |
| Q4 2017 | +3.3% | +4.1% | +1.3% | |
| Q3 2017 | +5.8% | +11.7% | +6.6% | |
| Q2 2017 | -0.1% | +0.4% | +9.3% | |
| Q1 2017 | -0.5% | -0.1% | +7.4% | |
| Q4 2016 | +2.0% | +1.9% | -3.0% | |
| Q3 2016 | -5.1% | -7.7% | +2.5% | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro